Sold as Verquvo. Every FDA application for this active ingredient: 1 branded and 2 generic.
As of Nov 15, 2026, FDA lists 3 applications for Vericiguat (sold as Verquvo), first approved Jan 19, 2021, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Verquvo | Part D | $64.8M | +30% | 13,414 |
| Metabolic Changes in Heart Failure Patients Treated With VericiguatHeart Failure, Worsening Heart Failure · University of Salerno | — | Not yet recruiting | Oct 28, 2026 |
| Vericiguat Use and Incident Atrial Fibrillation in Chronic Heart FailureChronic Heart Failure · Beijing Tsinghua Chang Gung Hospital | — | Active, not recruiting | Oct 16, 2026 |
| Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis ProgressionCalcific Aortic Valve Disease, AORTIC VALVE DISEASES · West China Hospital | Phase 2 | Recruiting | Jul 20, 2026 |
| Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Heart Failure PatientsHeart Failure With Reduced Ejection Fraction (HFrEF) · National Institute of Cardiovascular Diseases, Pakistan | Phase 4 | Not yet recruiting | Jul 13, 2026 |
| Micro-axial Flow Pump-Supported PCI in Complex Coronary Artery Disease With Ischemic LV DysfunctionCoronary Artery Disease (CAD) · China National Center for Cardiovascular Diseases | Not applicable | Not yet recruiting | Jul 1, 2026 |
| Efficacy of Verciguat in TR and RV FailureHFrEF, Tricuspid Regurgitation (TR) · Daejeon St. Mary's hospital | Phase 4 | Not yet recruiting | Jun 25, 2026 |
| Perioperative Vericiguat in Patients Undergoing Cardiovascular SurgeryCardio Vascular Disease, Cardiopulmonary Bypass · Nanjing Medical University | Not applicable | Not yet recruiting | May 18, 2026 |
| Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG TrialDecompensated Heart Failure · Khawaja Danish Ali | Phase 1 | Recruiting | Mar 2, 2026 |
| Jan 19, 2021 | VerquvoNDA 214377 · New molecular entity | Msd | 3 | Marketed |
| — | VericiguatANDA 220221 | Torrent Pharmaceuticals Ltd | 0 | Discontinued |
| — | VericiguatANDA 220264 | Changzhou Pharmaceutical Factory | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
